Indien trägt heute etwa bei 22 Prozent der Gesamtmenge generische Produktion by volume, drittgrößter Pharmaexporteur und wertmäßig elftgrößter Hersteller. Während COVID-19 gab es bisher einen Wendepunkt in der Geschichte der indischen Pharmaindustrie 2020 was positive Auswirkungen auf die Pharmaindustrie hatte. It was an opportunity to not only cater to the Indians but to the entire world”.’Indian pharma will contribute to play a similar kind of role going forward”.Indian pharma is at the forefront of tackling non-communicable diseases (NCDs) and emerging diseases with the understanding of technology and disease patterns as Indian pharma did in the case of developing vaccines for COVID-19 and also repurposed drugs for the same. “Indian pharma has crossed the rubicon of being the generic pharma producer in the world and therefore should look beyond as digitilisation will take it much ahead”,

“The Department of Pharmaceuticals (DoP) has launched schemes like bulk drug parks and has issued entrepreneurship and innovation policy guidelines.It should, Deshalb, adopt innovation hubs with all the players’ like researchers, Krankenhäuser, Wissenschaft, Aufsichtsbehörden, manufacturers and technology players at one place as is done in the west. The Centre will also encourage industry to invest in specific priority areas and there will centres of excellence for both pharma and medical devices going forward,"

Ikonische Marken